Pictet Asset Management Holding SA Increases Stake in Insulet Corporation $PODD

Pictet Asset Management Holding SA lifted its position in Insulet Corporation (NASDAQ:PODD) by 102.1% in the 1st quarter, Holdings Channel.com reports. The fund owned 85,177 shares of the medical instruments supplier’s stock after acquiring an additional 43,040 shares during the period. Pictet Asset Management Holding SA’s holdings in Insulet were worth $17,869,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Glenmede Investment Management LP lifted its stake in Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after purchasing an additional 35 shares during the last quarter. Curi Capital LLC lifted its stake in shares of Insulet by 0.8% during the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after acquiring an additional 36 shares during the last quarter. WINTON GROUP Ltd boosted its holdings in Insulet by 0.9% during the 3rd quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after acquiring an additional 37 shares during the period. Great Lakes Advisors LLC grew its position in Insulet by 1.5% in the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock valued at $791,000 after acquiring an additional 40 shares during the last quarter. Finally, Camarda Financial Advisors LLC grew its position in Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after acquiring an additional 40 shares during the last quarter.

Insulet Price Performance

PODD opened at $159.79 on Thursday. Insulet Corporation has a 12-month low of $138.79 and a 12-month high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. The business’s fifty day simple moving average is $156.37 and its 200-day simple moving average is $217.19. The company has a market capitalization of $11.07 billion, a price-to-earnings ratio of 37.16, a PEG ratio of 1.06 and a beta of 1.11.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same period in the previous year, the company posted $1.02 earnings per share. The firm’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts anticipate that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the acquisition, the director owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

PODD has been the subject of several research analyst reports. The Goldman Sachs Group reiterated a “buy” rating and set a $205.00 target price on shares of Insulet in a research report on Wednesday, May 27th. Canaccord Genuity Group reduced their price target on shares of Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Royal Bank Of Canada reiterated an “outperform” rating and set a $280.00 price objective on shares of Insulet in a report on Wednesday, May 27th. Wells Fargo & Company dropped their target price on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Finally, Benchmark restated a “buy” rating on shares of Insulet in a research note on Wednesday, May 27th. Twenty-two research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $238.67.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.